NCT03849651 · OUTCOME

The Cumulative Incidence of Any Grade Acute Graft-Versus-Host Disease (GVHD)

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies · Source last updated 2026-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: One year after receiving transplant

What was measured

Kalbfleisch and Prentice estimate of the percentage of experiencing any grade acute GVHD one year after the date of transplant. (Events=acute GVHD, competing events=death) Groups with insufficient events for confidence interval estimation have confidence intervals written as "NA to NA."

Analysis population: Patients who met eligibility criteria and received transplant.

Groups in this outcome

All Transplant Participants

Patients who met eligibility criteria and received transplant.

Dose 1

Patients who met eligibility criteria, received transplant, and received 1x10\^5 cells/kg

Dose 2

Patients who met eligibility criteria, received transplant, and received 1x10\^6 cells/kg

Dose 3

Patients who met eligibility criteria, received transplant, and received 1x10\^7 cells/kg

Phase 2

Patients who met eligibility criteria, received transplant, and were assigned the MED dose of 1x10\^7 cells/kg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Transplant Participants	69
Dose 1	9
Dose 2	10
Dose 3	10
Phase 2	40

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
All Transplant Participants	27.5	Not reported	17.6	38.4	Not reported
Dose 1	0	Not reported	NA	NA	No patients experienced outcome, so confidence interval is not applicable"?
Dose 2	50.0	Not reported	16.3	76.8	Not reported
Dose 3	30.0	Not reported	6.2	59.3	Not reported
Phase 2	27.5	Not reported	14.7	41.9	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
17.6
upper Limit
38.4
value
27.5
comment
No patients experienced outcome, so confidence interval is not applicable"?
group Id
OG001
lower Limit
NA
upper Limit
NA
value
0
group Id
OG002
lower Limit
16.3
upper Limit
76.8
value
50.0
group Id
OG003
lower Limit
6.2
upper Limit
59.3
value
30.0
group Id
OG004
lower Limit
14.7
upper Limit
41.9
value
27.5

denoms

counts
group Id
OG000
value
69
group Id
OG001
value
9
group Id
OG002
value
10
group Id
OG003
value
10
group Id
OG004
value
40
units
Participants

description

dispersion Type

95% Confidence Interval

groups

description
Patients who met eligibility criteria and received transplant.
id
OG000
title
All Transplant Participants
description
Patients who met eligibility criteria, received transplant, and received 1x10\^5 cells/kg
id
OG001
title
Dose 1
description
Patients who met eligibility criteria, received transplant, and received 1x10\^6 cells/kg
id
OG002
title
Dose 2
description
Patients who met eligibility criteria, received transplant, and received 1x10\^7 cells/kg
id
OG003
title
Dose 3
description
Patients who met eligibility criteria, received transplant, and were assigned the MED dose of 1x10\^7 cells/kg
id
OG004
title
Phase 2

param Type

NUMBER

population Description

Patients who met eligibility criteria and received transplant.

reporting Status

POSTED

time Frame

One year after receiving transplant

title

The Cumulative Incidence of Any Grade Acute Graft-Versus-Host Disease (GVHD)

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice